Artivion (NYSE:AORT) CAO Amy Horton Sells 6,000 Shares

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 6,000 shares of Artivion stock in a transaction on Monday, November 17th. The stock was sold at an average price of $45.73, for a total value of $274,380.00. Following the sale, the chief accounting officer directly owned 135,380 shares of the company’s stock, valued at approximately $6,190,927.40. This trade represents a 4.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Amy Horton also recently made the following trade(s):

• On Thursday, November 13th, Amy Horton sold 3,482 shares of Artivion stock. The stock was sold at an average price of $45.86, for a total value of $159,684.52.
• On Monday, November 10th, Amy Horton sold 1,789 shares of Artivion stock. The stock was sold at an average price of $44.62, for a total value of $79,825.18.

Artivion Trading Up 0.7%

Shares of NYSE:AORT traded up $0.32 during mid-day trading on Tuesday, reaching $45.44. The stock had a trading volume of 149,362 shares, compared to its average volume of 433,748. The firm has a 50 day simple moving average of $42.72 and a two-hundred day simple moving average of $36.51. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.04. The firm has a market cap of $2.15 billion, a PE ratio of -108.26 and a beta of 1.65. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. The firm had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business’s revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, research analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Citizens Jmp raised their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. LADENBURG THALM/SH SH lowered shares of Artivion from a “buy” rating to a “neutral” rating and upped their target price for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Needham & Company LLC lifted their price target on Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Artivion in a research report on Friday, November 7th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $49.11.

Institutional Investors Weigh In On Artivion

Several hedge funds have recently added to or reduced their stakes in AORT. Invesco Ltd. boosted its holdings in shares of Artivion by 27.9% during the 1st quarter. Invesco Ltd. now owns 341,656 shares of the company’s stock worth $8,398,000 after buying an additional 74,589 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in Artivion during the second quarter worth approximately $669,000. Fred Alger Management LLC acquired a new position in shares of Artivion in the first quarter valued at approximately $2,969,000. Diker Management LLC bought a new position in Artivion during the first quarter worth about $369,000. Finally, Atria Investments Inc acquired a new position in Artivion in the 2nd quarter valued at $244,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.